Israeli biotech claims it has developed cure for cancer
pharmafile | January 30, 2019 | News story | Research and Development | Cancer, MuTaTo, biotech, israel, lung cancer, oncology
An Israeli biotech has claimed that it has developed a complete cure for cancer.
Speaking to the Jerusalem Post, Dan Aridor, the chairman of Accelerated Evolution Biotechnologies Ltd (AEBi) said: “We believe we will offer in a year’s time a complete cure for cancer.”
“Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market,” Aridor said. “Our solution will be both generic and personal.”
According to Aridor, and AEBi CEO Dr Ilan Morad, the firm’s treatment, called MuTaTo (multi-target toxin), is on the scale of a cancer antibiotic.
MuTaTo uses a combination of three cancer cell targeting peptides together with a strong peptide toxin in order to kill cancer cells while also limiting mutations. Morad claims that MuTaTo will kill cancer stem cells and slow growing cancer cells thus ridding the body of cancer entirely.
The treatment has however only been tested in mice so far. Speaking to CNBC, Les Funtleyder, health-care portfolio manager at E Squared Capital Management, said: “I’d love there to be a cure for cancer, but I do not believe them in the absence of good human evidence.”
Although the company has not yet published any clinical evidence showing that the treatment works in humans, Morad claims that the therapy inhibited cancer cell growth in mice.
The company later clarified in an email to CNBC, suggesting: “complete cure for cancer meaning that we will have the complete solution ready for first tryout in humans. A solution that is supposed to finish the problem without it coming back. Even in the unlikely event that it comes back it can be re-administered\re-adjusted.”
Louis Goss
Related Content
Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by …
